| Literature DB >> 25756799 |
Erika M Yazawa1, Jenna E Geddes-Sweeney1, Filiberto Cedeno-Laurent1, Kempland C Walley1, Steven R Barthel2, Matthew J Opperman1, Jennifer Liang1, Jennifer Y Lin2, Tobias Schatton2, Alvaro C Laga3, Martin C Mihm2, Abrar A Qureshi4, Hans R Widlund1, George F Murphy3, Charles J Dimitroff5.
Abstract
Galectin-1 (Gal-1)-binding to Gal-1 ligands on immune and endothelial cells can influence melanoma development through dampening antitumor immune responses and promoting angiogenesis. However, whether Gal-1 ligands are functionally expressed on melanoma cells to help control intrinsic malignant features remains poorly understood. Here, we analyzed expression, identity, and function of Gal-1 ligands in melanoma progression. Immunofluorescent analysis of benign and malignant human melanocytic neoplasms revealed that Gal-1 ligands were abundant in severely dysplastic nevi, as well as in primary and metastatic melanomas. Biochemical assessments indicated that melanoma cell adhesion molecule (MCAM) was a major Gal-1 ligand on melanoma cells that was largely dependent on its N-glycans. Other melanoma cell Gal-1 ligand activity conferred by O-glycans was negatively regulated by α2,6 sialyltransferase ST6GalNAc2. In Gal-1-deficient mice, MCAM-silenced (MCAM(KD)) or ST6GalNAc2-overexpressing (ST6(O/E)) melanoma cells exhibited slower growth rates, underscoring a key role for melanoma cell Gal-1 ligands and host Gal-1 in melanoma growth. Further analysis of MCAM(KD) or ST6(O/E) melanoma cells in cell migration assays indicated that Gal-1 ligand-dependent melanoma cell migration was severely inhibited. These findings provide a refined perspective on Gal-1/melanoma cell Gal-1 ligand interactions as contributors to melanoma malignancy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25756799 PMCID: PMC4466041 DOI: 10.1038/jid.2015.95
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551